OBJECTIVE: CD8+ T cells are abundant in rheumatoid arthritis (RA). However, their role in disease pathogenesis is poorly defined. This study was undertaken to investigate the relationship between disease activity and CD8+ T cell phenotypes, production of cytokines, and production of cytotoxic molecules in the peripheral blood (PB) and synovial fluid (SF) of patients with RA. METHODS: CD8+ T cell phenotypes were determined in 96 patients with RA (44 with disease in remission, 34 with active disease, 18 with low disease activity) and in 64 sex- and age-matched healthy controls. Ten paired PB and SF samples from patients with active RA were analyzed. The expression of surface markers, cytokines, and proteolytic enzymes in CD8+ T cells was evaluated using flow cytometry. RESULTS: PB CD8+ T cells from RA patients with active disease exhibited an effector (CD27-CD62L-) phenotype (P = 0.005), with elevated expression of proinflammatory cytokines (tumor necrosis factor α [TNFα], interferon-γ [IFNγ], interleukin-6 [IL-6], IL-17A) when compared to healthy controls. In a state of remission, the same phenotype observed in patients with active disease persisted, including a significant increase in the frequency of CD69 (P < 0.001), but lower cytokine production was observed. SF CD8+ T cells from RA patients expressed more robust effector memory (CD27+CD62L-) and activated (CD69+) profiles compared to the T cell subsets in paired PB samples. Production of cytokines (IL-6, IL-17A, and IFNγ) by CD8+ T cells from RA PB was positively correlated within individual donors. Moreover, production of cytokines (TNFα, IFNγ, and IL-17A) by CD8+ T cells from RA PB positively correlated with the Disease Activity Score in 28 joints. CONCLUSION: The activation status and proinflammatory potential of CD8+ T cell subsets observed in the RA patients in this study strongly suggest that a phenotype of local and systemic cytotoxic effector T cells plays a role in this disease.
OBJECTIVE:CD8+ T cells are abundant in rheumatoid arthritis (RA). However, their role in disease pathogenesis is poorly defined. This study was undertaken to investigate the relationship between disease activity and CD8+ T cell phenotypes, production of cytokines, and production of cytotoxic molecules in the peripheral blood (PB) and synovial fluid (SF) of patients with RA. METHODS:CD8+ T cell phenotypes were determined in 96 patients with RA (44 with disease in remission, 34 with active disease, 18 with low disease activity) and in 64 sex- and age-matched healthy controls. Ten paired PB and SF samples from patients with active RA were analyzed. The expression of surface markers, cytokines, and proteolytic enzymes in CD8+ T cells was evaluated using flow cytometry. RESULTS: PB CD8+ T cells from RApatients with active disease exhibited an effector (CD27-CD62L-) phenotype (P = 0.005), with elevated expression of proinflammatory cytokines (tumor necrosis factor α [TNFα], interferon-γ [IFNγ], interleukin-6 [IL-6], IL-17A) when compared to healthy controls. In a state of remission, the same phenotype observed in patients with active disease persisted, including a significant increase in the frequency of CD69 (P < 0.001), but lower cytokine production was observed. SF CD8+ T cells from RApatients expressed more robust effector memory (CD27+CD62L-) and activated (CD69+) profiles compared to the T cell subsets in paired PB samples. Production of cytokines (IL-6, IL-17A, and IFNγ) by CD8+ T cells from RA PB was positively correlated within individual donors. Moreover, production of cytokines (TNFα, IFNγ, and IL-17A) by CD8+ T cells from RA PB positively correlated with the Disease Activity Score in 28 joints. CONCLUSION: The activation status and proinflammatory potential of CD8+ T cell subsets observed in the RApatients in this study strongly suggest that a phenotype of local and systemic cytotoxic effector T cells plays a role in this disease.
Authors: Alessandra Petrelli; Gerdien Mijnheer; David P Hoytema van Konijnenburg; Maria M van der Wal; Barbara Giovannone; Enric Mocholi; Nadia Vazirpanah; Jasper C Broen; Dirkjan Hijnen; Bas Oldenburg; Paul J Coffer; Sebastian J Vastert; Berent J Prakken; Eric Spierings; Aridaman Pandit; Michal Mokry; Femke van Wijk Journal: J Clin Invest Date: 2018-08-02 Impact factor: 14.808
Authors: Luisina I Onofrio; Estefania R Zacca; Paola Ferrero; Cristina Acosta; Eduardo Mussano; Laura Onetti; Isaac Cadile; M Victoria Gazzoni; Raúl Jurado; Jimena Tosello Boari; Maria C Ramello; Carolina L Montes; Adriana Gruppi; Eva V Acosta Rodríguez Journal: Arthritis Rheumatol Date: 2018-08-06 Impact factor: 10.995
Authors: Marina I Arleevskaya; Olga A Kravtsova; Julie Lemerle; Yves Renaudineau; Anatoly P Tsibulkin Journal: Front Microbiol Date: 2016-08-17 Impact factor: 5.640
Authors: Réka Kugyelka; Lilla Prenek; Katalin Olasz; Zoltán Kohl; Bálint Botz; Tibor T Glant; Timea Berki; Ferenc Boldizsár Journal: Cells Date: 2019-05-24 Impact factor: 6.600
Authors: Alexander Puck; Stefan Hopf; Madhura Modak; Otto Majdic; Petra Cejka; Stephan Blüml; Klaus Schmetterer; Catharina Arnold-Schrauf; Jens G Gerwien; Klaus S Frederiksen; Elisabeth Thell; Judith Leitner; Peter Steinberger; Regina Aigner; Maria Seyerl-Jiresch; Gerhard J Zlabinger; Johannes Stöckl Journal: Eur J Immunol Date: 2016-10-31 Impact factor: 5.532